outperform
reason report
brand price medic gener deflat management
commun dg mp
bottom line downgrad share market
perform recent medacorp survey show level distributor
rfp activ may increas could lead price
pressur survey data show signific portion client
view competit price
qualiti score lag mp op survey also
believ steadi gener deflat still major headwind
believ heavili depend januari price increas
may disappoint medic divis within continu
face major persist challeng cordi core medic busi
also seem slow stock ralli sinc
earn though view qualiti earn report low
market perform pt
survey data favor recent commiss medacorp
survey pharmaci order assess trend drug distribut
channel data show signific portion client
view best price level switch rfp
activ increas significantli rel last year
qualiti score survey believ
custom renew activ high year like lead
on-going pharma margin pressur rais sell-sid price
risk attrit increas especi specialti capabl lag peer
stabl gener deflat equal gener
deflat accord proprietari analysi nadac data
believ gener deflat rate remain fairli high level consist
last year term stabl use somewhat
frequent variou manag team stabl y/i declin
gener price suggest stabl signific declin gener
earn accord data fda anoth record
year term gener approv tent approv
believ mean gener price pressur continu next year
brand inflat headwind mid-singl digit brand price increas
januari seem like reason expect us howev
estim brand price increas typic occur januari
risk price-hik come low-end
expect furthermor rebat go away rate list price
inflat also like slow long-term
net debt total capit
ep
year price history/av daili volume mil
creat bluematrix
compani inform leerink partner llc research
revenu present billion dollar
adj dilut ep continu oper
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
pharma divis face competit market
survey data show switch rate pharmaci
higher vs
custom survey suggest provid best
price also face major renew op
contract run june odd earli renew
high may lead even pharma margin pressur
assum test market effort implement
competit price possibl rfp activ
spread provid rise opioid cost also risk
possibl state follow new york lead suspect
lawyer work case everi incent extend
process year even decad
medic divis face major issu exclud
inventori charg estim medic divis
oper incom declin y/i concern
especi given fact patient recoveri busi
larg contributor medic face on-going slew issu
includ rise commod price cordi integr highli
competit market may win share
mp believ risk reduc price significantli order
keep busi increas given turmoil compani face
commun challeng believ
commun investor challeng
best past year sever guide-down
worri ramp requir make guidanc
steep indic call corpor oper
incom would remain flat sequenti mean ramp earn
requir back-half year substanti given
headwind highlight report risk anoth guide-down high
view
downgrad market perform lower pt
downgrad share mp stock trade near
high share ralli sinc report earn
fundament longer justifi outperform rate manag
commun investor challeng gener deflat
brand inflat still face signific challeng risk
medic divis perform well expect
reduc estim lower pt
one largest pharmaceut distributor countri one
major cardin busi base pharmaceut distribut
medical-surg suppli distribut ancillari support servic jv
reli redoak drug purchas consortium sourc pharmaceut product
estim redoak gener market share allow sourc product
competit rate serv pharmaci specialti
pharmaci suppli relationship hospit util level
remain somewhat depress industri believ done good job
execut tuck-in acquisit grow footprint faster grow market segment includ
home health medic surgic distribut includ recent acquisit medtron patient
recoveri busi cordi addit though sold distribut busi china
compani retain presenc help sourc higher margin prefer
product add cardin product portfolio like cash-flow
characterist busi provid abil leverag larg fix cost
infrastructur model leverage- face sever on-going
headwind includ gener deflat risk brand inflat rate cordi integr
difficult commun investor challeng given system
challeng headwind market see abat time soon rate
share market perform
downgrad market perform risk abound
downgrad market perform outperform recent drug
distribut survey show market becom aggress rfp activ
potenti switch activ distributor recent client satisfact level
also lowest believ price higher rate last
year may lead attrit long-term addit survey data
impress cah result believ numer risk headwind
continu gener deflat may stabl steadi y/i declin gener
rate signific headwind estim like lead y/i declin pharma
oper incom consensu seem assum pharma
oper incom remain flat though believ risk anoth y/i declin
substanti medic divis also perform poorli integr cordi
consist challeng brand price may issu januari elimin reduct
rebat flow channel may also caus brand inflat slow view would
long-term neg shown resili past month
aforement headwind signific downgrad market perform
survey data favor
recent commiss medacorp conduct survey pharmaci order assess
trend pharmaci distribut market pleas see note today titl survey show drug
distribut price challeng continu full report data survey view
unfavor market particular
behind specialti tabl see survey
respond purchas specialti product compar
view show still lag behind regard
specialti capabl mean cah competit posit market behind
survey last year show trend
figur lag specialti
switch rate year higher headwind sell-sid margin pressur
chart see pharmaci survey indic plan
switch new distributor next rfp process compar last year
survey clear winner rather said new distributor tbd
spread evenli last year share gainer
though seem chang interpret data mean sell-sid pressur
increas
figur switch rate higher year
buy brand gener specialti drug primari distributor totalbrand brandsgener genericsspecialti inc
face share loss tabl see face
share loss accord survey sampl respond clear winner
respond said winner tbd categor appear us like cah
win rate slow materi last year
figur face potenti share loss
may rais price part survey ask pharmaci rank
distributor overal price scale lowest price see data
got highest score across respond consid
custom rank primari distributor view may tri hold line
price effort expand pharma margin view unfavor may ultim
lead share loss
figur may rais price
may get less competit price tabl see
respond survey use howev said think give
best price client said give best price
client said give best price worri may
face share loss remain competit
yet take rfp could three othervalu drug better rebat loss unknown approach rfp process determin could anywin easier deal offer analyt better definit loss remain still unknown go bid depend gpo one could stay take current distributor survey win loss analysi survey respond would rank distributor price cost highest cost would rank distributor price cost highest cost inc
figur price seen aggress client
also ask pharmaci particip rate qualiti servic
receiv distributor scale best see score
behind declin overal qualiti score improv
score along higher price caus us worri may face share loss
signific pharma margin headwind futur
figur score well qualiti analysi
data tabl distributor survey much
thorough analysi survey result found companion note today survey
show drug distribut price challeng continu data survey appear
unfavor distribut group believ price pharma margin
challeng continu
outlook appear issu
guid effect lower manag affirm guidanc
report result manag continu expect adj ep rang
howev benefit tax benefit
distributortotaln said said said said said said high survey primari provid best scale best would rate qualiti servic distributor unfamiliar enter inc
includ guid sinc guidanc affirm effect view inclus
tax benefit reduct core guid
high-singl low-doubl digit percentag declin y/i
mid high-singl digit percentag growth y/i
flat oper profit guid impli massiv
enterpris adj oper profit flat q/q one biggest take-away
cah earn call compani expect adj oper profit dollar
enterpris flat sequenti cah cfo jorg gomez explain
noth call special yield result find commentari
surpris prior estim call enterpris adj op
consensu prior estim well ahead report
despit substanti neg surpris expect adj oper profit manag
continu expect adj ep rang discret
tax benefit provid support guidanc impli ramp earn
signific view adj oper profit guid impli substanti weak
medic segment on-going headwind pharmaceut divis
new adjust oper profit estim segment assum
y/i declin far aggress unfavor manag guidanc
high-singl low-doubl digit percentag declin y/i achiev flat enterpris adj
oper profit q/q appear result medic segment come well
behind prior leerink/consensu estim neg surpris
view medic divis includ inventori charg overal find
adj oper profit guid surpris troubl given impli adj op
ramp significantli achiev manag guidanc target
view given numer headwind cite manag struggl medic
segment continu work believ guid risk
brand price increas occur primarili januari heighten
price scrutini could hamper
risk ramp brand price fail achiev manag assumpt
recent analyz price data im pricerx show
fewer brand price increas far year-to-d septemb compar
rate price increas bp behind last year link analysi includ top
drug base im sale togeth sampl repres total
brand drug univers sale drug
heighten polit scrutini amid trump administr push lower drug price appear
even though manufactur continu take price increas may fewer
manufactur increas price januari cah
figur price increas ytd trail featur greater concentr
drug price increas occur januari analysi also found vast major
drug price increas occur januari cah record price increas
januari januari estim octob januari
account price increas second frequent month increas juli
account price increas octob examin
see clearli januari frequent month price increas
view present risk cah impli ramp
price chang thru drug per drug averag price price brand drugstop brand drug four differ drug increas later revert origin price omit count one octob chang price decreas merck co drug price increas base aggreg level price go result end period end year price respect inc
figur price increas predominantli occur januari juli
price hike concentr januari amidst fewer price increas
overal base analysi im pricerx data see
price hike januari rel januari price hike month seen
lower frequenc increas septemb year find
price chang behind price chang total price
chang occur januari occur januari believ
januari critic month guid brand price increas mid-
singl digit believ rang certainli achiev howev also believ
odd beat fairli low certainli see brand price tailwind
distribut group
manag comment indic import januari price increas
right manufactur ceo mike kaufmann recent present investor
confer septemb explain doesnt expect lot inflat
januari howev januari remain key guidanc year
us everi year januari alway biggest month biggest
month littl biggest month lot vast major brand
inflat rememb less conting rest inflat
matter januari could vendor rais price
could still fine right vendor rais price less
conting inflat conting vendor largest portion
occur januari second largest month typic juli distant
consist find mr kaufmann explain januari import month
price increas juli distant second import light comment
come away concern impli ramp heighten scrutini trump
administr drug price polit scrutini like follow democrat win
hous believ risk fewer lower price hike januari signific
manag keep say less brand portfolio conting price
estim cah fee brand side tie list price usual distributor
charg percent wholesal acquisit wac distribut fee
brand busi carri meaning inventori mean brand price increas
high import still tie list price slow-down rate
brand inflat headwind distribut group
manag reduc guidanc post weak result sent stock
tumbl ad concern impli ramp perform
miss consensu adj ep estim lower
guidanc provid disappoint earli outlook sent stock
tumbl prior close last quarter beat consensu adj
ep estim time revenu estim time adj ebitda
perform spotti beat rate gener view qualiti
adjust ep fairli low ebitda beat rate import
guidanc process difficult tabl show manag histori
guidanc estim three period unfavor adjust
guidanc benefit ep tax reform still view qualiti
guidanc set process low guid reduc overal
view qualiti commun investor manag fairli low
like manag visibl busi also challeng
figur guidanc process difficult
earningsrevenuelow-singl digit percentag growthlow-singl digit percentag growthpharma segment revenuelow-singl digit percentag growthlow-singl digit percentag growthmed segment revenuelow-singl digit percentag growthlow-singl digit percentag growthadj segment oper profithigh-singl low-doubl digit percentag declinehigh-singl low-doubl digit percentag declinemed segment oper profitmid high-singl digit percentag growthmid high-singl digit percentag earningsrevenuemid-singl digit percentag growth y/ymid-singl digit percentag growth y/ymid-singl digit percentag growth y/ymid-singl digit percentag growth y/ypharma segment revenuelow- mid-singl digit percentag increas y/ylow- mid-singl digit percentag increas y/ylow- mid-singl digit percentag increas y/ylow- mid-singl digit percentag increas y/ymed segment revenuehigh-teen percentag increas y/yhigh-teen percentag increas y/yhigh-teen percentag increas y/yhigh-teen percentag increas y/yadj segment oper profitdown low-doubl digit y/ydown low-doubl digit y/ydown low-doubl digit y/ydown high-singl low-doubl digit y/ymed segment oper profitstrong double-digit segment profit growth y/ystrong double-digit segment profit growth y/ystrong double-digit segment profit growth y/ystrong double-digit segment profit growth y/ygener drug price assumptionsmid-singl digit deflat full fymid-singl digit deflat full fymid-singl digit deflat full fymid-to-high singl digit deflat full fybrand drug price inflat full inflat full inflat full inflat full earningsrevenuehigh-singl digit percentag growth y/yhigh-singl digit percentag growth y/yhigh-singl digit percentag growth y/ymid-to-high singl digit percentag growth y/ypharma segment revenuehigh-singl digit percentag increas y/yhigh-singl digit percentag increas y/yhigh-singl digit percentag increas y/ymid-to-high singl digit percentag increas y/ymed segment revenuemid-singl digit percentag increas y/ymid-singl digit percentag increas y/ymid-to-high-singl digit percentag increas y/yhigh-singl digit percentag increas y/yadj segment oper profitessenti flat y/ydown mid-to-high singl digit y/ydown high-singl low-doubl digit y/ydown low-doubl digit y/ymed segment oper profitdouble-digit segment profit growth y/ydouble-digit segment profit growth y/ydouble-digit segment profit growth y/ydouble-digit segment profit growth y/ygener drug price assumptionsmid-singl digit deflat full fymid-to-high singl digit deflat full fyhigh-singl digit deflat full fylow-doubl digit deflat full fybrand drug price assumptionsapproxim inflat full inflat full inflat full inflat full fy cardin inc
medic continu under-perform
medic continu whiff past highlight medic divis
close achiev long-tout oper margin goal howev becom appar
sever quarter poor perform continu headwind unlik
achiev margin time soon furthermor oper profit segment shown
substanti declin recent quarter adjust inventori charg relat patient
recoveri busi detract result face headwind
segment oper profit inventori step charg
correct charg find cah medic oper profit growth
y/i model y/i declin oper margin face
signific y/i declin rang
what even concern medic divis manag guid
accret talk interest expens
patient recoveri deal impli earn patient recoveri busi
estim oper profit medic divis patient recoveri alon
exclud medic appear either guid patient recoveri
accret simpli way high core medic busi deterior rapid rate
either way view medic divis signific issu challeng
see turn-around divis time soon furthermor februari cfo
jorg gomez indic us medic divis oper margin normal basi
near goal subsequ miss guide-down gener lack
visibl concern us
inc incom statement model fiscal year end june revenu y/i revenu oper profit y/i oper profit profit margin expans y/i margin chang y/i inc
cost headwind off-set y/i comp benefit medic segment
experienc comp benefit inventori step-up charg incur
brand cost cordi headwind larg off-set benefit look
ahead concern manag guid flat oper incom
enterpris even though medic divis comp benefit due inventori
charg believ cordi challeng increment cost continu
year
opioid litig could expand introduc
opioid cost could expand mount defens piec
litig earn manag disclos expect incur total
opioid relat cost exclud adj result
catch-up accrual accord manag relat compani activ
year remain factor guidanc impact adj result
enterpris mani cost relat new york opioid stewardship act
note level cost roughli consist guid howev
discuss compani appear mani cost also relat
on-going litig defend wide array plaintiff sound though
current compani incur cost due ton discoveri estim legal
process associ legal fee may continu year even decad
concern action state could add yet anoth headwind compani need
contract renew present yet anoth risk could lead
continu margin pressur
renew upcom optum renew like weigh margin renew
contract optum though renew loom compani typic
discuss contract renew provid clariti contract
contract set expir june indic us earli
renew possibl assum earli renew happen could put
pressur cah margin add yet anoth element risk ramp
impli manag guidanc though growth larg custom
good cah top-lin manag attribut y/i revenu growth
pharma divis growth exist custom renew larg custom often
featur aggress price weigh margin
figur cah pharma divis oper margin pressur
save initi progress
suggest poor oper histori past
save progress well ahead expect one bright spot
cardin cost save plan explain progress well
manag previous set annual save goal annual goal
though compani implement person labor forc reduct
septemb cost save far reportedli exceed cah intern expect
manag explain expect initi ramp throughout year cfo jorg
gomez highlight believ compani like exceed mark
find encourag howev discuss compani cost save
initi explain primarili driven work forc reduct employe
hire freez anoth posit cost save chang explain
includ polici chang like ensur employe book hotel compani travel
websit like cost reduct effort believ big enough
off-set fundament challeng face medic pharma divis
commod headwind continu manag appear
limit visibl
commod price headwind like persist accord manag neg
surpris cfo jorg gomez anticip inflat commod cost
due forward curv believ comment suggest manag littl visibl
futur commod price manag claim hard provid inflat rate
basket commod plagu medic divis inflat pressur remain high
earn call manag explain continu expect input cost inflat
direct indirect commod manag explain expos
manufactur busi direct commod cost indirectli affect area
buy finish product glove manag work minim
impact report stabil program track continu acceler
commod headwind remain risk view
price trend medic divis input increas estim substanti
portion cah medic divis product face price inflat made three
petroleum-deriv plastic polyvinyl chlorid pvc butadien acrylonitril nitril glove
made nitril butadien rubber compos butadien acrylonitril
butadien help tear resist flexibl glove acrylonitril lend chemic
resist properti common plastic use medic surgic distribut pvc use
varieti product includ vinyl glove corrobor manag claim continu
input cost inflat examin spot price three compon pvc price
increas sinc bottom februari novemb
figur pvc price uptrend
forecast commod exposur upcom fiscal yeara june june gains-to-loss given gains-to-loss given longer provid cardin inc
three petroleum-deriv product examin acrylonitril experienc greatest
price inflat howev note acrylonitril content variou nitril glove
shown vari among brand link said spot price risen sinc bottom
figur acrylonitril price continu inflat
butadien spot price pull back recent also show signific increas price
sinc bottom novemb
figur butadien price moder also increas
difficult forecast commod price potenti headwind creat continu
price increas cardin face cost attribut brand
product includ cordi may partli attribut input cost inflat
stabl gener deflat still headwind like continu gener deflat
appear though continu stabil could character posit
howev gener deflat continu view unlik abat pose
headwind distributor steadi y/i declin price gener product
continu translat lower earn distributor year analysi nadac
data center medicar medicaid servic highlight though gener
deflat stabil signific deflat continu show gener brand
trend equal weight analysi nadac data includ discount rebat
report retail pharmaci in-depth explan pleas see
distribut preview link also consist nadac data kol comment
brand inflat trend rang
figur nadac data show stabil continu gener deflat
gener deflat like continu fda remain aggress drug approv
support view gener deflat continu fda drug approv data show
agenc remain aggress attempt combat rise drug price new
gdufa ii report requir fda disclos mean median approv time
highlight chang fda made approv gener drug increas market
competit median approv time drop day day
reduct well median approv time tent approv ta drop
day day
figur fda work aggress reduc approv time
total action set new record amid continu rhetor aggress action
fda includ recent releas list game tactic link agenc continu
set record drug approv data show total number approv
tent approv came record year previou record year
figur fda activ report show record number total action
new fda report format fda decjan marapr junjul-sepanda await fda ta await await applic ap approv ap approv ta taprov ta taprov fda document data repres snapshot time statu distinct origin anda per fda mani applic resubmit ta tent approv ap first full approv anda await applic ta receiv ta drug remain patent exclus period final approv delay mean/median time calcul interv date origin applic accept ap ta divid averag day per month activ yearpre-gdufa supplement submiss backlog approv approv tent supplement respons origin receiv master file complet assess fdanot fiscal year begin octob conclud septemb tent approv ta anda meet statutori requir approv approv period unexpir exclus refer list drug rld referenc anda tent approv anda consid pend applic anda workload applic must submit amend tent approv anda request full approv fda requir addit review fda prior approv supplement pa prior approv supplement submiss allow compani make chang product alreadi approv anda cder must approv import anda chang packag ingredi instanc ensur condit origin set product still met sourc complet respons cr letter written commun applic dmf holder fda usual describ defici agenc identifi abbrevi applic includ pend amend dmf must satisfactorili address anda approv complet respons letter reflect complet review requir complet respons industri restart clock citizen petit cp may impact approv anda fda strive address possibl valid issu rais relev cp cr letter cp rais issu would delay part cr respons address issu consid cr refus receiv refus file applic drug master file type ii activ pharmaceut ingredi drug master file -- submiss inform secretari person intend author food drug administr refer inform support approv gener drug submiss without submitt disclos inform gener drug submiss applic inc
valuat attract may seem
valuat attract may seem view cah current valuat
attract may seem current trade averag ntm
price-to-earnings basi ntm ev/ebitda basi believ metric may mislead shown
nadac chart featur signific gener price inflat substanti
benefit drug distributor period averag valuat like appropri
growth profit level exceed tradit run-rat howev inclus
period averag multipl provid distort effect view look
horizon see current multipl much close in-lin valuat
normal market environ gener inflat period though
also true stock tax reform also impact comparison histori ntm price-to-earnings
make current valuat appear even favor
figur trade in-lin ev/ebitda averag
figur cah trade ntm pe averag
downgrad market perform
mani headwind believ simpli mani headwind risk
face justifi outperform rate believ price pressur go increas
ramp gener deflat may remain steadi steadi deflat rate still
massiv headwind group brand price inflat also come pressur may
disappoint januari medic divis face signific challeng cordi
also believ core medic busi issu easili
identifi given patient recoveri acquisit sentiment stock fickl
guidanc re-affirm may see investor buy stock view
sentiment valuat reach floor view fundament still remain
challeng risk neg guidanc revis high
stock trade ep estim well
histor ntm price-to-earnings averag rel ep trade
trade next month
expect share trade ep would put stock
headwind includ on-going gener deflat brand price drug price reform
possibl elimin rebat cordi given challeng risk
estim rate share mp
risk valuat
competit intens custom concentr high compet
op mp well sever smaller medic
surgic distributor includ owen minor mp inc op
result competit custom buy-sid sell-sid may constantli tri
pressur margin novat premier larg custom present renew risk
lose custom custom put signific margin
pressur compani earn could come pressur
price could declin reform also pose risk price brand name
drug gener declin time margin could come
pressur addit patient protect afford act health
educ reconcili act implement signific chang industri exampl
increas rebat paid manufactur fee must paid could advers
impact buy-sid margin abl earn addit retail
pharmaci face margin pressur due chang medicaid reimburs chang
awp could pressur compani sell-sid margin
regul extens drug distribut busi subject extens law
regul cover mani aspect compani oper includ fraud abus
law prescript drug pedigre track mani requir mandat
fda state feder law agenc compani requir hold
licens permit oper distribut center
tax posit pose risk oper mani state throughout
world tax law complex within intern perspect
addit ever refin lifo account could advers impact
inform system compani reli inform system within corpor
offic throughout distribut center technolog system complex
requir facilit purchas distribut thousand inventori line-item receiv
process ship order manag bill collect process payment mani
function reason technolog system fail function properli
earn could face substanti risk
acquisit integr could risk perform fair number
acquisit past sever year may continu acquir futur
compani fail integr acquisit onto platform inform
technolog personnel structur issu integr process compani
earn could risk
concentr supplier pose risk supplier make
revenu five supplier gener compani busi contract typic
written one-year basi automat renew year five year given
somewhat high degre concentr among manufactur
depend honor supplier agreement relationship end
deterior manufactur put price pressur
compani earn could risk addit depend raw materi
commod includ nuclear materi price oil impact distribut
econom trend compani global oper impact econom trend
exampl recess could caus patient less will go physician
offic certain procedur done out-of-pocket cost could view substanti
peopl unemploy worri becom unemploy howev
econom trend overal employ improv medical-surg distribut busi
incom statement model fiscal year end june
million
good sold
total revenu
total revenu
sale carefus stock
loss debt extinguish
weight average number share
incom statement model fiscal year end june
million
margin expans bp
margin expans bp
